Related Experiment Videos
Single-dose intravenous melphalan in advanced multiple myeloma
1Department of Medicine, Ostra Hospital, Gothenburg University, Sweden.
Abstract:
Eight patients with progressive multiple myeloma were given an intermediate intravenous dose of melphalan (30 mg/m2). A response lasting 2-18 months was observed in 7 patients. The bone marrow toxicity was well acceptable and most courses could be given on an outpatient basis. Intermediate-dose intravenous melphalan may be considered an alternative for treatment of relapsing or progressive multiple myeloma, even if the patient has previously received oral melphalan.
Insights
Intermediate-dose intravenous melphalan showed significant efficacy in treating progressive multiple myeloma. This treatment offers a viable option for patients with relapsing or progressive disease, even after prior oral melphalan therapy.
Area of Science:
- Hematology
- Oncology
- Clinical Pharmacology
Background:
- Multiple myeloma is a progressive plasma cell malignancy.
- Effective treatment options for relapsing or progressive multiple myeloma are crucial.
Purpose of the Study:
- To evaluate the efficacy and tolerability of intermediate-dose intravenous melphalan in patients with progressive multiple myeloma.
Main Methods:
- Eight patients with progressive multiple myeloma received intravenous melphalan at a dose of 30 mg/m2.
- Patient responses and bone marrow toxicity were monitored.
Main Results:
- Seven out of eight patients experienced a response lasting 2-18 months.
- Bone marrow toxicity was acceptable, allowing for outpatient administration in most cases.
Conclusions:
- Intermediate-dose intravenous melphalan is an effective treatment for relapsing or progressive multiple myeloma.
- This regimen is a potential alternative, even for patients previously treated with oral melphalan.